LOI Template & Negotiation Guide for Acquiring a Telehealth Platform

Parties and Transaction Overview

Identifies the buyer entity, seller entity, and the legal structure of the proposed transaction — asset purchase, stock purchase, or merger. For telehealth platforms, most lower middle market transactions are structured as asset purchases to isolate regulatory and HIPAA liability, though buyers seeking to preserve payer contracts or state licenses may push for a stock purchase where contract assignment restrictions would otherwise apply.

💡 Sellers should push back on a reflexive asset purchase structure if they have Medicare Advantage or commercial payer contracts with strict anti-assignment clauses — losing those contracts in a restructure can materially reduce deal value. Buyers should confirm during LOI negotiation whether key contracts require consent to assignment and build a consent-solicitation timeline into the exclusivity period. If offshore developers contributed to the codebase, confirm IP assignment status before committing to an asset purchase that includes software IP.

Purchase Price and Valuation Basis

States the proposed aggregate purchase price, the valuation methodology, and how the price was derived relative to the platform's ARR, gross margin, and contract backlog. Telehealth platforms in the $1M–$5M revenue range typically trade at 3.5x–6x ARR, with premium multiples reserved for platforms with diversified payer contracts, sub-10% annual churn, and proprietary clinical workflows that are not easily replicated.

💡 Sellers should insist that the valuation basis be explicitly anchored to verified ARR — not total revenue — and that any post-close reimbursement policy changes affecting revenue not be used retroactively to claw back purchase price. Buyers should define ARR conservatively, excluding one-time implementation fees, grant revenue, or COVID-era emergency billing that is unlikely to recur. If the platform derives meaningful revenue from Medicare telehealth flexibilities currently subject to congressional reauthorization, both parties should negotiate a reimbursement risk adjustment mechanism.

Earnout Structure

Defines the post-close contingent payment mechanism, which is common in telehealth acquisitions given reimbursement uncertainty and the need to validate that ARR is durable under new ownership. Earnouts in this sector are typically tied to ARR growth or retention milestones over a 12–24 month post-close period, with specific provisions addressing how payer contract renewals and platform integration decisions by the buyer affect earnout achievement.

💡 Sellers must negotiate explicit anti-sandbagging protections prohibiting the buyer from restructuring the platform in ways that make earnout milestones unachievable — such as migrating patients to a different platform, terminating key payer contracts, or repricing below market. Buyers should ensure earnout calculations exclude revenue attributable to post-close integrations or cross-sell activity from the buyer's existing portfolio. Consider a hybrid structure where 50% of the earnout triggers on ARR and 50% on gross margin retention to protect against top-line growth that sacrifices unit economics.

Due Diligence Contingencies

Specifies the conditions that must be satisfied during the due diligence period for the buyer to remain obligated to proceed, with telehealth-specific carve-outs for HIPAA compliance findings, IP ownership deficiencies, reimbursement model verification, and technology stack assessments. This section sets the buyer's exit ramps and signals to the seller which diligence findings would be deal-breakers versus price-adjustment triggers.

💡 Sellers should provide a well-organized data room at LOI signing to compress the due diligence timeline and reduce buyer leverage to retrade on price. A clean third-party HIPAA assessment completed within the prior 12 months is one of the highest-ROI investments a seller can make before going to market. Buyers should treat unresolved BAA gaps or missing IP assignment agreements from offshore contractors as price-reduction triggers rather than automatic deal-killers — remediation is often feasible within the exclusivity period.

Exclusivity

Grants the buyer a defined period of exclusive negotiation during which the seller may not solicit or entertain other offers. For telehealth platforms in the lower middle market, exclusivity periods typically run 45–75 days, reflecting the complexity of HIPAA diligence, technology stack review, and provider contract verification required before a definitive agreement can be drafted.

💡 Sellers should resist exclusivity periods exceeding 60 days without a clearly defined diligence checklist and milestone schedule — open-ended exclusivity stalls competing interest and gives buyers leverage to retrade. Buyers should negotiate for extension rights tied to specific outstanding diligence items such as pending HIPAA assessment results or payer contract consent responses. Both parties should agree upfront on a bi-weekly check-in cadence to keep diligence moving and surface deal-stopping issues early.

Transition and Seller Retained Role

Addresses the seller's post-close involvement, which is particularly important in telehealth acquisitions where founder-operators often hold clinical relationships, platform access credentials, and institutional knowledge of payer contracting history that cannot be transferred through documentation alone. This section defines the duration, compensation, and scope of a transition services agreement or clinical advisor arrangement.

💡 Buyers should be specific about which relationships and knowledge assets require seller involvement — vague transition obligations breed disputes. Sellers should ensure the transition services agreement includes a clear scope of work, defined working hours, and indemnification protection for actions taken in good faith on behalf of the buyer post-close. If the seller is a physician whose personal NPI or DEA registration is embedded in the platform's prescribing workflows, this must be explicitly addressed before closing.

Representations and Warranties Outline

Previews the key seller representations that will be included in the definitive agreement, giving both parties a shared understanding of the compliance and operational warranties at stake. In telehealth transactions, representations around HIPAA compliance, IP ownership, reimbursement model legitimacy, and state licensure carry elevated risk profiles that buyers frequently seek to backstop with rep and warranty insurance or escrow arrangements.

💡 Sellers should push for a knowledge qualifier on HIPAA and data security representations — representing that there are 'no data breaches to Seller's knowledge' is defensible; representing absolute compliance with all HIPAA technical safeguards is not. Buyers in competitive processes may offer rep and warranty insurance to bridge indemnification gaps, which can allow the seller escrow to be reduced or eliminated. Both parties should agree on the indemnification basket and cap during LOI negotiations to avoid protracted definitive agreement disputes.

Confidentiality

Confirms that both parties are bound by confidentiality obligations regarding the transaction and any proprietary information exchanged during diligence, typically referencing a previously executed NDA. In telehealth transactions, confidentiality provisions must address protected health information separately from business confidential information, given that HIPAA governs the handling and disclosure of PHI independently of contractual NDA terms.

💡 Buyers conducting technology stack diligence should never access live patient data environments without a BAA in place — doing so creates HIPAA liability for both parties regardless of NDA protections. Sellers should set up a sandboxed or de-identified data environment for technology review purposes. Both parties should confirm which diligence participants are bound by the NDA, particularly if the buyer is using third-party technical consultants or a healthcare IT advisory firm.

Binding and Non-Binding Provisions

Clearly delineates which sections of the LOI are legally binding and which are expressions of intent only. In telehealth acquisitions, binding provisions typically include exclusivity, confidentiality, and conduct-of-business obligations, while purchase price, deal structure, and representations are non-binding until a definitive agreement is executed.

💡 Sellers should confirm that the conduct-of-business obligation — which typically requires them to operate the platform in the ordinary course during exclusivity — does not prohibit necessary actions such as renewing expiring payer contracts, credentialing new providers, or resolving identified HIPAA findings. Buyers should not treat the LOI as a license to delay definitive agreement negotiations; sellers can and do walk away from LOIs where buyers use the exclusivity period to conduct endless diligence without progressing toward a signed deal.